NCT06927349

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BA1301 in Advanced Solid Tumors.

An Non-randomized Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy of BA1301in Participants With Advanced Solid Tumors.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Shandong Boan Biotechnology Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open label Phase 1, First in Human trial designed to evaluate the safety, tolerability pharmacokinetics, preliminary efficacy of BA1301 in participants with advanced solid tumors.

Conditions

• Advanced Solid Tumours

Interventions

Type	Name	Description
DRUG	BA1301	BA1301 is administered intravenously once every three weeks.

Timeline

• Start date: 2023-01-11
• Primary completion: 2026-06-30
• Completion: 2026-12-31
• First posted: 2025-04-15
• Last updated: 2025-04-15

Locations

1 site across 1 country: China